Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1401-1420 of 3,900 trials

Allergic Rhinitis: New Immunotherapy for Dust Mite Allergy

We are studying a new treatment for people aged 12 to 65 with allergic rhinitis caused by house dust mites. The trial will evaluate its effectiveness and safety compared to a placebo.

Allergic Rhinitis and Asthma1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesAllergologyInternal Medicine

Allergic Rhinitis: New Immunotherapy for House Dust Mite Allergy

We are studying a new treatment for people aged 12 to 65 with allergic rhinitis caused by house dust mites. The trial will evaluate its effectiveness and safety compared to a placebo.

Allergic Rhinitis and Asthma6-12 monthsConfirmation phase (III)Investigational MedicinesAllergologyPulmonology

Crimean Congo Hemorrhagic Fever: N-pVAX1 Vaccine Study

We are evaluating a new DNA vaccine to see if it is safe and can help the body fight against Crimean Congo Hemorrhagic Fever. This study is for healthy volunteers who want to contribute to vaccine research.

Congo-Crimean Hemorrhagic FeverSafety phase (I)Infectious Diseases

Lupus Nephritis: Ianalumab Study

We are studying whether ianalumab can improve kidney function in people with active lupus nephritis compared to a placebo. This trial also looks at the safety and tolerability of the treatment.

Lupus Nephritis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteNephrologyRheumatology

Advanced Head and Neck Cancer: TG4050 Gene Therapy

We are testing a personalized gene therapy for patients with advanced head and neck cancer. The goal is to see if it can improve treatment outcomes compared to standard options.

Head and Neck Squamous Cell Carcinoma>2 yearsSafety phase (I)Efficacy phase (II)OncologyOtolaryngology

Neuroendocrine Tumors: Personalized vs. Standard RadioTherapy

We are comparing personalized radionuclide therapy with standard treatment for patients with neuroendocrine tumors. The goal is to see which approach is safer and more effective in shrinking tumors and improving quality of life.

Neuroendocrine Tumors6-12 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Kidney Health in Type 2 Diabetes: Empagliflozin and Finerenone Study

We are exploring how well two medications work for kidney health in people with type 2 diabetes. This remote trial aims to personalize treatment based on individual responses.

Type 2 DiabetesAlbuminuria≤3 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesPartially RemoteDiabetologyInternal MedicineNephrology

Multiple Myeloma: Treatment-Free Interval Study

We are exploring whether a treatment-free interval is safe and effective for newly diagnosed multiple myeloma patients receiving a combination of Daratumumab, Lenalidomide, and Dexamethasone. The study aims to compare the effects of continuous treatment versus a break in therapy.

Multiple Myeloma>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

High-Risk Neuroblastoma: Naxitamab and GM-CSF Treatment

We are studying a new treatment combining naxitamab and GM-CSF for children with high-risk neuroblastoma who have not responded to prior therapies. The trial aims to assess how well this treatment works and its safety.

Recurrent Neuroblastoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncologyPediatrics

Multiple Myeloma: AZD0305 Treatment Study

We are investigating whether AZD0305, alone or with other cancer therapies, is safe and effective for adults with relapsed or refractory multiple myeloma.

Relapsed or Refractory Multiple MyelomaSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Metastatic Breast Cancer: FDG-PET/CT vs. Conventional CT

We are studying whether FDG-PET/CT can better monitor treatment response in metastatic breast cancer patients compared to conventional CT. This may help improve survival and quality of life for those involved.

Metastatic Breast Cancer>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Pancreatic Cancer: Gembrax with Folfirinox

We are studying whether adding Gembrax to the standard Folfirinox treatment helps patients with metastatic pancreatic cancer. This trial aims to find out if the combination is more effective than Folfirinox alone.

Metastatic Pancreatic Cancer>2 yearsEfficacy phase (II)GastroenterologyOncology

Preventing Blood Clots: REGN9933 and REGN7508 Study

We are studying two new medications to see if they can help prevent blood clots in adults with a peripherally inserted central catheter. The trial will also assess how safe these treatments are.

Venous Thromboembolism3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyHematology

Hyponatremia: Empagliflozin Treatment Study

We are investigating whether empagliflozin can help increase sodium levels in patients with euvolemic or hypervolemic hyponatremia. The study will also look at its effects on related symptoms and overall health.

Low Sodium Levels (Hyponatremia)≤3 monthsEfficacy phase (II)≤5 visitsStandard MedicinesEndocrinologyInternal Medicine

Advanced Melanoma: Vusolimogene Oderparepvec with Nivolumab

We are comparing a new treatment combination for advanced melanoma that has worsened after other therapies. The goal is to see if this combination improves survival and response compared to standard treatment options.

Advanced MelanomaConfirmation phase (III)No PlaceboInvestigational MedicinesDermatologyOncology

Head and Neck Cancer: Dostarlimab Treatment Study

We are studying whether dostarlimab can improve outcomes for adults with locally advanced head and neck cancer after initial treatment. Participants will receive either the new treatment or a placebo to compare effects.

Squamous Cell Carcinoma of the Head and Neck3-6 monthsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementOncology

Graft-Versus-Host Disease: Corticosteroids with ECP

We are studying whether adding extracorporeal photopheresis to corticosteroids helps patients with Grade II acute graft-versus-host disease after stem cell transplantation. This trial compares treatment outcomes and side effects between the two approaches.

Acute Graft-Versus-Host Disease (GVHD)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

BRAF V600E Mutated Metastatic Colorectal Cancer: ENCORAFENIB and FOLFIRI

We are studying a combination of ENCORAFENIB and FOLFIRI for patients with BRAF V600E mutated metastatic colorectal cancer that has progressed on previous treatments. The goal is to see if this combination can improve treatment outcomes and safety.

Colorectal Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

HIV Treatment Comparison: Doravirine vs. Dolutegravir

We are studying whether doravirine is as effective as dolutegravir for people newly diagnosed with HIV-1. The trial also examines potential side effects and health changes over time.

HIV Infection>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

HIV and HBV Co-Infection: Antiviral Treatment Strategies

We are studying two treatment reduction strategies for patients co-infected with HIV-1 and HBV to see how safely they can manage their viral infections. The trial will also look at the impact on quality of life and any potential side effects.

Co-infection with HIV-1 and HBV>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHepatologyInfectious Diseases